Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 7/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 12/20 | 0.65 |
| ▸ | PTPRF | P10586 | 2/20 | 0.65 |
| ▸ | CDC25B | P30305 | 2/20 | 0.65 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29808966 | 0.79 | PTPN1 (1.00) | PTPRCPTPN1PTPRFCDC25BBACE1 | |
| SCHEMBL6236312 | 0.79 | PTPN1 (1.00) | PTPRCPTPN1PTPRFCDC25BBACE1 | |
| SCHEMBL8600693 | 0.78 | PTPN1 (0.75) | PTPRCPTPN1PTPRFCDC25BBACE1 | |
| SCHEMBL6231543 | 0.76 | PTPRC (1.00) | PTPRCPTPN1PTPRFCDC25BBACE1 | |
| SCHEMBL6236908 | 0.74 | PTPRC (1.00) | PTPRCPTPN1PTPRFCDC25BBACE1 | |
| Dimethylamine SCHEMBL7487471 | 0.73 | PTPN1 (0.85) | PTPRCPTPN1PTPRFCDC25BBACE1 | |
| SCHEMBL3699448 | 0.71 | PTPN1 (1.00) | PTPRCPTPN1PTPRFCDC25BBACE1 | |
| SCHEMBL8596446 | 0.71 | PTPN1 (0.64) | PTPRCPTPN1PTPRFCDC25BBACE1 | |
| SCHEMBL2529860 | 0.70 | PTPRC (0.59) | PTPRCPTPN1PTPRFCDC25BNSD2 | |
| SCHEMBL7487467 | 0.69 | PTPN1 (0.67) | PTPRCPTPN1PTPRFCDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939896-B2 | Naphthalenedione derivatives; treating autoimmune diseases and organ graft rejection | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | claimed |
| EP-1259231-B1 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | EP | claimed |
| US-20030119897-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | claimed |
| EP-1259231-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | claimed |
| WO-2001045681-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| US-6939896-B2 | Naphthalenedione derivatives; treating autoimmune diseases and organ graft rejection | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| EP-1259231-B1 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| US-20030119897-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | US | disclosed |
| EP-1259231-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001045681-A2 | NAPHTHOQUINONE DERIVATIVES AS CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119897-A1 | Cd45 inhibitors | PTPRC, CD2, HLA-C | PTPRC 1/4885PTPN1 18/4885PTPRF 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.